Injured brain endothelial cells release neurotoxic thrombin.
The multifunctional serine protease thrombin has been shown to be neurotoxic in vitro and in vivo and is demonstrable in the Alzheimer disease (AD) brain. We have documented that in AD the cerebral microvasculature is a source of inflammatory and neurotoxic proteins. The objective of this study was to determine if injured brain endothelial cells could be a source of neurotoxic thrombin. Brain endothelial cells were incubated with either sodium nitroprusside (SNP, 10 microM), inflammatory proteins (IL-1beta, IL-6, TNFalpha, LPS, IFNgamma) or the PKC inhibitor bisindolymaleimide (1 microM) for 24 h and conditioned media collected. Endothelial cell conditioned medium was incubated with purified apolipoprotein E4 (apoE4) for 24 h, and then analyzed for neurotoxic activity against primary cortical cultures and for apoE4 fragments by western blot. Endothelial cell conditioned medium collected after treatment with either SNP, inflammatory proteins, or the PKC inhibitor bisindolymaleimide, demonstrated a significant (p < 0.005) level of thrombin activity, the presence of apoE4 fragments, and was capable of evoking neuronal cell death. These data demonstrate that endothelial cell injury results in thrombin release and suggest that the brain microcirculation could be a source of neurotoxic factors in AD.
Grammas
Paula
P
Department of Pathology, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA. paula-grammas@ouhsc.edu
Ottman
Todd
T
Reimann-Philipp
Ulrich
U
Larabee
Jason
J
Weigel
Paul H
PH
D000544:Alzheimer Disease / Q000378:metabolism* / Q000473:pathology*; D000818:Animals; D001057:Apolipoproteins E / Q000096:biosynthesis*; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D001921:Brain / Q000098:blood supply / Q000378:metabolism / Q000473:pathology*; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D007211:Indoles / Q000008:administration & dosage / Q000494:pharmacology; D007371:Interferon-gamma / Q000008:administration & dosage / Q000494:pharmacology; D007375:Interleukin-1 / Q000008:administration & dosage / Q000494:pharmacology; D015850:Interleukin-6 / Q000008:administration & dosage / Q000494:pharmacology; D008301:Maleimides / Q000008:administration & dosage / Q000494:pharmacology; D008833:Microcirculation / Q000502:physiology; D009599:Nitroprusside / Q000008:administration & dosage / Q000493:pharmacokinetics; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D051381:Rats; D013917:Thrombin / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000494:pharmacology
D001057:Apolipoproteins E; D007211:Indoles; D007375:Interleukin-1; D015850:Interleukin-6; D008301:Maleimides; D014409:Tumor Necrosis Factor-alpha; D009599:Nitroprusside; D007371:Interferon-gamma; D011493:Protein Kinase C; D013917:Thrombin; C088060:bisindolylmaleimide